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neutropenia (FN) in chemotherapy regimens with a high risk of
FN, pegﬁlgrastim was recently shown to decrease the relative risk
of FN by 0.94 in regimens with a moderate risk (<20%). We esti-
mated the cost-effectiveness ($ per FN episode avoided, $/life
year gained [LYG]) of pegﬁlgrastim primary (starting in cycle 1)
vs. secondary (after FN) prophylaxis in women with early-stage
breast cancer receiving chemotherapy with a moderate risk of
FN. METHODS: We created a decision-analytic model from a
payor’s perspective. The base case considers costs and outcomes
related to reduced FN. Secondary analyses considered potential
survival beneﬁts due to reduced FN-related mortality, and
cancer-speciﬁc long-term survival gains due to increased
chemotherapy dose intensity. Costs included drug costs, FN-
related hospitalizations and post-hospitalization costs. FN risk
and mortality, risk of chemotherapy relative dose intensity (RDI)
<85%, hazard ratio for mortality with RDI <85%, and risk
reduction with pegﬁlgrastim were based on a comprehensive lit-
erature review. Breast cancer mortality by stage and age-speciﬁc
mortality from other causes were obtained from Surveillance
Epidemiology and End Results and National Vital Statistics
Reports. Result robustness was tested using multi-way sensitiv-
ity analyses. RESULTS: For women with stage II breast cancer
receiving chemotherapy with FN risk of 17%, the incremental
cost-effectiveness ratio (ICER) was $41 K per FN episode
avoided. Adding survival beneﬁt due to avoiding FN mortality
yielded an ICER of $72 K/LYG. Adding all proven and hypoth-
esized beneﬁts yielded an ICER of $54 K/LYG. Factors that were
most inﬂuential for the base case ICER included (in order of
inﬂuence) study time horizon, FN case-fatality, baseline FN risk,
FN relative risk reduction, and cost of pegﬁlgrastim. CON-
CLUSION: The value of pegﬁlgrastim primary prophylaxis in
early-stage breast cancer is favorable compared with other oncol-
ogy therapies.
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OBJECTIVES: To assess the cost-effectiveness of breast cancer
risk assessment in primary care, with chemoprevention with
tamoxifen offered to high-risk women. METHODS: A Markov
model was developed to simulate the incidence, health conse-
quences, and costs of invasive breast cancer (IBC) and other clin-
ical events associated with a 5-year course of tamoxifen. Cohorts
at ages 50, 55, and 60 were stratiﬁed by 5-year cancer risk based
on the Gail model. Treatment criteria were deﬁned according to
alternative risk thresholds of 1.67% to 6%. Acceptance of (70%)
and compliance with (68%) chemoprevention were assumed to
be imperfect. Women receiving tamoxifen were assumed to be at
decreased risk for IBC and vertebral fracture, and increased risk
for endometrial cancer, stroke, and venous thromboembolic
events. Breast cancer incidence and survival were derived from
SEER. Other model parameters, including costs and utilities,
were estimated from published literature and clinical trial data.
We discounted costs (2006 US dollars) and quality-adjusted life
years (QALYs) at 3%/year. RESULTS: For 50-year-old women,
risk assessment and chemoprevention based on a 5-year cancer
risk of 4% or greater results in an incremental cost-effectiveness
ratio (ICER) of $49,900 compared to no risk assessment.
Expanding the criterion for chemoprevention to 3%, 2%, and
1.67% leads to incremental cost-effectiveness ratios of $54,400,
$106,000, and $163,000 per QALY, respectively. Thresholds
higher than 4% were weakly dominated. At age 60, ICERs
ranged from $35,300 to $1.3 million per QALY as the treatment
threshold was lowered from 6% to 1.67%. At age 65, thresh-
olds below 5% were dominated. CONCLUSION: Risk assess-
ment and chemoprevention is cost-effective at a $100 K/QALY
threshold at ages 50–65, but more selective criteria for chemo-
prevention at older ages is required to achieve any given cost-
effective criterion.
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OBJECTIVES: In HR positive ABC, HT may be considered stan-
dard treatment before institution of chemotherapy. However, HT
is sometimes substituted by CT early in the disease course, for
example after failure of ﬁrst-line HT. A common treatment
sequence in Brazil is anastrozole followed by successive lines of
docetaxel, capecitabine and gemcitabine. We evaluated the CE
of this treatment sequence (CT sequence) compared to several
other sequences (HT/CT sequences) in which anastrozole and
fulvestrant are used in ﬁrst and second lines, respectively, and
then followed by exemestane and megestrol or megestrol 
and capecitabine or exemestane and capecitabine or megestrol
and exemestane or exemestane and docetaxel, each pair intro-
duced as third and fourth lines, respectively. METHODS: A
Markov model describing the clinical history of HR positive,
ABC, projected improvements in terms of quality-adjusted life
months (QALM), costs, and CE of CT compared to HT/CT. The
time horizon is four treatment lines or the time to patient’s death,
whichever occurred ﬁrst. The simulations were with 10,000
patients for each treatment sequence studied. The reference
patient is a post-menopausal woman with HR positive ABC,
with previous deﬁnitive surgery and adjuvant HT with tamox-
ifen. The disease-progression probabilities for the different treat-
ment drugs/lines and, the quality of life for each health state were
based on the medical literature. Local management and costs of
each health state was based on a Delphi panel, according to the
private health care perspective. Outcomes were discounted at
3% annually. RESULTS: The CE of CT sequence in relation to
HT/CT sequences ranged from R$ 15,000 to R$ 552,000 per
QALM gained. CONCLUSION: As WHO-recommended cost-
utility threshold for Brazil is R$ 2435.75 per QALM gained, CT
is not cost effective in relation to treatment sequences contain-
ing successive lines of HT with fulvestrant in the second line and
introducing chemotherapy in later lines.
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OBJECTIVES: This study is an economic evaluation of currently
recommended colorectal cancer (CRC) screening procedures,
and strategies that incorporate chemopreventive options such as
aspirin or a cycooxygenase-2 inhibitor. METHODS: A decision
analysis model was constructed to compare alternative CRC
screening strategies. A Markov model was employed to simulate
the natural history of CRC. Markov states included Well, Well
with Polyp History, Well with CRC History, CRC-Local, CRC-
